Nandan Godani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nandan Godani has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Sanjay Sharma
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM’S NMIMS, Deemed to be University, Mumbai, India
3 shared publications - Saradhkumar Mudaliar
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Deemed to beUniversity, Vile Parle West, Mumbai, Maharashtra, 400056, India
2 shared publications - Anuj N. Nahata
Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM’s NMIMS-Deemed to be University, Mumbai, India
1 shared publication - Rohan Pai
Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, India
1 shared publication - Sudhanshu Kalantri
Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM’s NMIMS-Deemed to be University, Mumbai, India
1 shared publication
Latest Publications
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Current Analytical Chemistry
- Vol. 22 (2) , 185-198
Insights into the Chemistry, Pharmacokinetics and Analytical Techniques of Lobeglitazone: A Novel Anti-diabetic Drug
Objective: This review article aims to provide crucial insights related to the chemistry, pharmacology and analytical techniques associated with Lobeglitazone, a promising anti-diabetic molecule. Diabetes is a chronic ailment which hinders the normal functioning of beta pancreatic cells due to which the pancreas becomes incapable of producing sufficient amount of insulin or the body is not able to utilize the insulin that is produced by the beta-pancreatic cells. Lobeglitazone is a novel thiazolidinedione class of drug approved for type-II diabetes management by regulatory agencies in South Korea and India. The molecule has the potential to replace pioglitazone for the treatment of type-II diabetes due to its lower effective dose (0.5 mg) and better safety profile. Method: A comprehensive literature review was conducted using sources like PubMed, ScienceDirect, and Google Scholar. The review focused on chemistry, pharmacology, efficacy, safety, and advancements in analytical techniques for Lobeglitazone estimation in biological samples, bulk, and dosage forms. Result: Lobeglitazone exhibits potent therapeutic efficacy in treating type-II diabetes with fewer adverse effects compared to previous thiazolidinedione drugs. It demonstrates a better safety profile, especially in terms of cardiovascular risk. However, current analytical methods for lobeglitazone rely on solvents that do not adhere to green chemistry principles, highlighting the need for eco-friendly alternatives. Conclusion: Lobeglitazone holds substantial potential to replace older thiazolidinedione drugs due to its lower effective dose and improved safety profile. Future research should focus on developing sustainable analytical methods that align with green chemistry principles, further reinforcing its role in diabetes management.
- 1 February 2026
- Published by Bentham Science Publishers Ltd. in Current Analytical Chemistry
- Vol. 22 (2) , 185-198
Insights into the Chemistry, Pharmacokinetics and Analytical Techniques of Lobeglitazone: A Novel Anti-diabetic Drug
Objective: This review article aims to provide crucial insights related to the chemistry, pharmacology and analytical techniques associated with Lobeglitazone, a promising anti-diabetic molecule. Diabetes is a chronic ailment which hinders the normal functioning of beta pancreatic cells due to which the pancreas becomes incapable of producing sufficient amount of insulin or the body is not able to utilize the insulin that is produced by the beta-pancreatic cells. Lobeglitazone is a novel thiazolidinedione class of drug approved for type-II diabetes management by regulatory agencies in South Korea and India. The molecule has the potential to replace pioglitazone for the treatment of type-II diabetes due to its lower effective dose (0.5 mg) and better safety profile. Method: A comprehensive literature review was conducted using sources like PubMed, ScienceDirect, and Google Scholar. The review focused on chemistry, pharmacology, efficacy, safety, and advancements in analytical techniques for Lobeglitazone estimation in biological samples, bulk, and dosage forms. Result: Lobeglitazone exhibits potent therapeutic efficacy in treating type-II diabetes with fewer adverse effects compared to previous thiazolidinedione drugs. It demonstrates a better safety profile, especially in terms of cardiovascular risk. However, current analytical methods for lobeglitazone rely on solvents that do not adhere to green chemistry principles, highlighting the need for eco-friendly alternatives. Conclusion: Lobeglitazone holds substantial potential to replace older thiazolidinedione drugs due to its lower effective dose and improved safety profile. Future research should focus on developing sustainable analytical methods that align with green chemistry principles, further reinforcing its role in diabetes management.
- Open Access
- 4 October 2025
- Published by Springer Nature in Discover Pharmaceutical Sciences
- Vol. 1 (1) , 1-33
A comprehensive review on the integration of microneedle technologies with biosensing platforms for advancements in fabrication, biomarker detection, and therapeutic monitoring in precision medicine
- 4 October 2025
- Published by Springer Nature in Discover Pharmaceutical Sciences
- Vol. 1 (1) , 1-33
Open AccessA comprehensive review on the integration of microneedle technologies with biosensing platforms for advancements in fabrication, biomarker detection, and therapeutic monitoring in precision medicine
- 12 August 2024
- Published by Springer Nature in Chromatographia
- Vol. 87 (10) , 635-648
Leveraging Principles of QbD for Analytical Method Development and Validation for the Estimation of Eltrombopag Olamine in Tablet Dosage Forms by HPLC
- 12 August 2024
- Published by Springer Nature in Chromatographia
- Vol. 87 (10) , 635-648
Leveraging Principles of QbD for Analytical Method Development and Validation for the Estimation of Eltrombopag Olamine in Tablet Dosage Forms by HPLC
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Drug Metabolism Letters
- Vol. 17 (1) , 42-48
Rapid, Simple and Low-Cost Analytical Method Development for Quantification of Eltrombopag Olamine in Tablet Dosage by UV Spectroscopy Method
Background: Eltrombopag Olamine is a drug used to treat thrombocytopenia, a dis-order where blood platelet counts get lower and severe aplastic anemia. It serves as a thrombo-poietin receptor agonist, which give rise to platelet production in the bone marrow. Objectives: The objective of this study is to develop a simple, specific, accurate, precise and economical Ultraviolet spectroscopy method to estimate the amount of Eltrombopag Olamine in bulk and tablet dosage form. Methods: The developed method was performed using methanol for identification and physico-chemical characterization of the drug. The validation parameters like linearity, precision, accuracy, robustness limits of detection and quantitation, and specificity were assessed as per ICH Q2 (R2). Results: The maximum absorbance wavelength (λmax) of the drug was found at 247 nm in methanol. The linearity was found in the concentration range of 2-14 μg/ml with regression equation y = 0.0619x - 0.0123 and r² = 0.999. The standard addition method was used to deter-mine the accuracy of the developed method. The result was found in the % recovery range of 98-99%. The precision was done on λmax with respect to the parameters such as repeatability, intraday, and interday. The method was found to be precise as the % RSD value was found to be <2%. The detection limit value (LOD) and quantitation limit value (LOQ) were 0.0524 μg/ml and 0.1588 μg/ml, respectively. Conclusion: The developed method is simple, economical, accurate and selective. The developed method was adaptable for the estimation of Eltrombopag Olamine analysis in pharmaceutical dosage form and routine quality control laboratory.
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Drug Metabolism Letters
- Vol. 17 (1) , 42-48
Rapid, Simple and Low-Cost Analytical Method Development for Quantification of Eltrombopag Olamine in Tablet Dosage by UV Spectroscopy Method
Background: Eltrombopag Olamine is a drug used to treat thrombocytopenia, a dis-order where blood platelet counts get lower and severe aplastic anemia. It serves as a thrombo-poietin receptor agonist, which give rise to platelet production in the bone marrow. Objectives: The objective of this study is to develop a simple, specific, accurate, precise and economical Ultraviolet spectroscopy method to estimate the amount of Eltrombopag Olamine in bulk and tablet dosage form. Methods: The developed method was performed using methanol for identification and physico-chemical characterization of the drug. The validation parameters like linearity, precision, accuracy, robustness limits of detection and quantitation, and specificity were assessed as per ICH Q2 (R2). Results: The maximum absorbance wavelength (λmax) of the drug was found at 247 nm in methanol. The linearity was found in the concentration range of 2-14 μg/ml with regression equation y = 0.0619x - 0.0123 and r² = 0.999. The standard addition method was used to deter-mine the accuracy of the developed method. The result was found in the % recovery range of 98-99%. The precision was done on λmax with respect to the parameters such as repeatability, intraday, and interday. The method was found to be precise as the % RSD value was found to be <2%. The detection limit value (LOD) and quantitation limit value (LOQ) were 0.0524 μg/ml and 0.1588 μg/ml, respectively. Conclusion: The developed method is simple, economical, accurate and selective. The developed method was adaptable for the estimation of Eltrombopag Olamine analysis in pharmaceutical dosage form and routine quality control laboratory.